rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    ENVB
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Enveric Biosciences Reports Financial Results for Third Quarter 2026 and Provides Corporate Update
      Nov 13Yahoo FinanceENVB
      Enveric Biosciences Reports Favorable Brain Activity Data for Lead Psychiatric Drug Candidate
      Nov 4BenzingaENVB
      Enveric Biosciences Reports Differentiated Brain Activity Profile for EB-003 in Preclinical qEEG Study
      Nov 4Yahoo FinanceENVB
      Enveric completes drug absorption studies for EB-003 candidate
      Oct 21Investing.comENVB
      Enveric Biosciences Reports Favorable Preclinical Results for Non-Hallucinogenic Psychiatric Candidate
      Oct 21BenzingaENVB
      Enveric Biosciences Announces Positive Results from Recently Completed IND-enabling ADMET Studies
      Oct 21Yahoo FinanceENVB
      Enveric receives U.S. patent allowance for psychiatric compounds
      Sep 15Investing.comENVB
      Enveric Biosciences Secures New U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 Series

      CAMBRIDGE, Mass., September 15, 2026--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a patent application covering novel compounds within its EVM401 Series of drug candidates. The EVM401 Series comprises proprietary, non-hal

      Sep 15Yahoo FinanceENVB
      Enveric Biosciences to Present at H.C. Wainwright 28th Annual Global Investment Conference

      CAMBRIDGE, Mass., September 01, 2026--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced that Joseph Tucker, Ph.D., CEO of Enveric will deliver a virtual presentation at the H.C. Wainwright 28th Annual Global Investment Conference, which is being held September 14-16, 2026, in New York City.

      Sep 1Yahoo FinanceENVB

      This is the newest page. Registered accounts read further back.